Alterity Therapeutics Limited

NasdaqCM ATHE

Alterity Therapeutics Limited Price to Book Ratio (P/B) on December 05, 2024

Alterity Therapeutics Limited Price to Book Ratio (P/B) is NA on December 05, 2024, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Alterity Therapeutics Limited 52-week high Price to Book Ratio (P/B) is NA on December 05, 2024, which is NA below the current Price to Book Ratio (P/B).
Alterity Therapeutics Limited 52-week low Price to Book Ratio (P/B) is NA on December 05, 2024, which is NA below the current Price to Book Ratio (P/B).
Alterity Therapeutics Limited average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: ATHE

Alterity Therapeutics Limited

CEO	Dr. David A. Stamler M.D.
IPO Date	Sept. 29, 2003
Location	Australia
Headquarters	460 Bourke Street
Employees	10
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Key trends

Past 5 years